Corbus Pharmaceuticals Holdings

CRBP

Biotechnology · Healthcare

Also trades as: 0SZI.L

Exchange

NASDAQ

Winston Score

–

No score yet — Winston is napping.

We couldn’t gather enough financial data to score this stock reliably.

Track this stock — start free trial

Winston Score History

The full picture

Corbus Pharmaceuticals is a small biotech company that develops experimental drugs to treat serious diseases. Its main focus is on cancer treatments, particularly a drug called CRB-701, which targets a protein called Nectin-4 found on certain tumor cells. The company does not yet sell any approved products and is in the clinical trial stage, meaning its drugs are still being tested in humans.

Corbus makes no revenue from product sales right now. It funds its operations through stock offerings and occasionally through partnerships or grants, which is common for early-stage biotechs. The company is based in the United States and has a very small market cap of around $200 million, reflecting the high uncertainty of its pipeline. The biggest risk it faces is running out of cash before its drug candidates can prove they work well enough to win regulatory approval — a challenge that sinks many small biotechs before they ever reach the market.

Growth Profile

For growth stock investors

When traditional metrics don't capture the full picture, these are the signals growth stock investors use instead.

Revenue Growth

Revenue data limited

EPS Growth

-25.7% YoY

YoY Growth Rate

Earnings declining

Insider Activity

22.7%ownership

↑ Rising

Insiders increasing their stake — aligned with shareholders

Cash Runway

~12 months

$118M cash & investments

Quarterly Free Cash Flow

↓ Burn rate worsening

Adequate runway but may need to raise capital within 2 years

The Winston Score above measures business quality today. Growth stocks often score lower because they invest in the future rather than maximising current profits. These metrics show what matters most for evaluating that future.

Score breakdown

Every number that matters to educated investors.

Each metric is explained in plain language so you know exactly what you're looking at. Start your free trial now.

Quality

Profit per sale

Gross Margin

N/A

—

Data not available

Profit after running costs

Operating Margin

N/A

—

Data not available

Return on the money invested

ROCE

-104.5%

Weak — -104.5% return on capital

Negative ROIC means the business is losing money on every dollar invested in it.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Growth

Sales growth

Sales YoY

N/A

—

Data not available

Profit growth

EPS YoY

N/A

—

Data not available

How steady the profit is

EPS Consistency

5/8 quarters

Mixed — about half the quarters showed growth

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Cash Flow

Profit that turns into cash

Cash Conversion

N/A

—

Data not available

Spare cash per sale

FCF Margin

N/A

—

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Stability

What it owes vs what it owns

Debt / Equity

N/A

Data not available

Covers its interest

Interest Cover

N/A

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Valuation

Price vs profit

P/E Ratio (TTM)

N/M

no trend

Negative earnings — P/E not meaningful

Cheaper or dearer next year

P/E vs Forward

N/A

not available

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Dividends

Not applicable for this business.

🔒 See full fundamentals and if they are improving or declining — click here for your free trial now.

Start free trial